ArticleInfectious diseases of poverty2017
Elimination of schistosomiasis: the tools required.
Article in Infectious diseases of poverty, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Core components, concepts and strategies for parasitic and vector-borne disease elimination with a focus on schistosomiasis: A landscape analysis.PLoS neglected tropical diseases · 2020Pooled it
- Performance of a real-time PCR approach for diagnosing Schistosoma haematobium infections of different intensity in urine samples from Zanzibar.Infectious diseases of poverty · 2020Trial
- Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) - single versus multiple praziquantel treatments in school-aged children in Côte d'Ivoire: a study protocol for an open-label, randomised controlled trial.BMC infectious diseases · 2018Trial
- Article
- Article
- Therapeutic challenges of schistosomiasis: mechanisms of action and current limitations.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Review
- Institutionalising urogenital schistosomiasis surveillance: Best practices to improve female genital and urinary schistosomiasis control in South Africa.PLoS neglected tropical diseases · 2025Article
- The impact and cost of a new rapid diagnostic test for school-based prevalence mapping and monitoring and evaluation surveys of schistosomiasis: A modelling study.PLoS neglected tropical diseases · 2025Article
- Cell-free DNA as a complementary diagnostic tool for neglected tropical diseases towards achieving the WHO NTDs elimination by 2030.The journal of liquid biopsy · 2025Article
- Significant Progress in the Study of African Freshwater Snails Over the Past 260 Years.Ecology and evolution · 2025Review
- One Health integrated surveillance: a way forward to accelerate schistosomiasis elimination in China.Science in One Health · 2025Review
- Prevalence, Intensity, and Risk Factors ofJournal of parasitology research · 2025Article
- Schistosomiasis transmission: A machine learning analysis reveals the importance of agrochemicals on snail abundance in Rwanda.PLoS neglected tropical diseases · 2024Article
- Chemical Control of Snail Vectors as an Integrated Part of a Strategy for the Elimination of Schistosomiasis-A Review of the State of Knowledge and Future Needs.Tropical medicine and infectious disease · 2024Review
- Exploring the interplay between climate change and schistosomiasis transmission dynamics.Infectious Disease Modelling · 2024Article
- Article
- The Current Distribution ofTropical medicine and infectious disease · 2023Article
- The characteristics of intestinal microbiota in patients with chronic schistosomiasisFrontiers in microbiology · 2023Article
- Article
- Environmental DNA in human and veterinary parasitology - Current applications and future prospects for monitoring and control.Food and waterborne parasitology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHistorically, the target in the schistosomiasis control has shifted from infection to morbidity, then back to infection, but now as a public health problem, before moving on to transmission control. Currently, all endemic countries are encouraged to increase control efforts and move towards elimination as required by the World Health Organization (WHO) roadmap for the global control of the neglected tropical diseases (NTDs) and the WHA65.21 resolution issued by the World Health Assembly. However, schistosomiasis prevalence is still alarmingly high and the global number of disability-adjusted life years (DALYs) due to this infection has in fact increased due to inclusion of some 'subtle' clinical symptoms not previously counted. MAIN BODY: There is a need to restart and improve efforts to reach the elimination goal. To that end, the first conference of the Global Schistosomiasis Alliance (GSA) Research Working Group was held in mid-June 2016 in Shanghai, People's Republic of China. It reviewed current progress in schistosomiasis control and elimination, identified pressing operational research gaps that need to be addressed and discussed new tools and strategies required to make elimination a reality. The articles emanating from the lectures and discussions during this meeting, together with some additional invited papers, have been collected as a special issue of the 'Infectious Diseases of Poverty' entitled 'Schistosomiasis Research: Providing the Tools Needed for Elimination', consisting of 26 papers in all. This paper refers to these papers and discusses critical questions arising at the conference related to elimination of schistosomiasis.
conclusionThe currently most burning questions are the following: Can schistosomiasis be eliminated? Does it require better, more highly sensitive diagnostics? What is the role of preventive chemotherapy at the elimination stage? Is praziquantel sufficient or do we need new drugs? Contemplating these questions, it is felt that the heterogeneity of the endemic areas in the world requires WHO policies to be upgraded instituting new, differentiated guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.